

SCORE Search Results Details for Application 10578781 and Search Result 20081104_154454_us-10-578-781-1.rng.

[Score Home Page](#) [Retrieve Application List](#) [SCORE System Overview](#) [SCORE FAQ](#) [Comments / Suggestions](#)

This page gives you Search Results detail for the Application 10578781 and Search Result 20081104_154454_us-10-578-781-1.rng.

[Go Back to previous page](#)

GenCore version 6.3
Copyright (c) 1993 - 2008 Bioccelerat ion Lt d.

OM nucleic - nucleic search, using sw model

Run on: November 4, 2008, 17:10:32 ; Search time 243 Seconds
(without alignments)
44258.760 Million cell updates/sec

Title: US-10-578-781-1

Perfect score: 756

Sequence: 1 at gggt gccgat at caaaaa.....aggagcaaatttgaacat tag 756

Scoring table: IDENTI TY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 11806651 seqs, 7113014948 residues

Total number of hits satisfying chosen parameters: 23613302

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_200808: *
1: geneseqn1980s: *
2: geneseqn1990s: *
3: geneseqn2000: *
4: geneseqn2001a: *
5: geneseqn2001b: *
6: geneseqn2002a: *
7: geneseqn2002b: *
8: geneseqn2003a: *
9: geneseqn2003b: *
10: geneseqn2003c: *
11: geneseqn2003d: *
12: geneseqn2004a: *
13: geneseqn2004b: *
14: geneseqn2004c: *
15: geneseqn2004d: *
16: geneseqn2004e: *
17: geneseqn2004f: *
18: geneseqn2005a: *
19: geneseqn2005b: *
20: geneseqn2005c: *
21: geneseqn2006a: *

```

22: geneseqn2006b:*
23: geneseqn2006c:*
24: geneseqn2006d:*
25: geneseqn2007a:*
26: geneseqn2007b:*
27: geneseqn2007c:*
28: geneseqn2007d:*
29: geneseqn2008:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	% Length	DB	ID	Description
1	756	100.0	756	18	AEA00728	Aea00728 Br evi baci
2	273.4	36.2	665	6	ABK78469	Abk78469 Bacillus
3	192.2	25.4	1438	12	ADN60500	Adn60500 B. lichen
4	178.2	23.6	777	21	AEH93992	Aeh93992 S. gG codi
5	173.8	23.0	381	6	ABK74144	Abk74144 Bacillus
6	147	19.4	631	6	ABK74048	Abk74048 Bacillus
7	78	10.3	1110	12	ADH97013	Adh97013 S. pneumo
8	78	10.3	1110	18	AEC13368	Aec13368 St repto oco
9	76.4	10.1	915	12	ADK44581	Adk44581 St repto oco
10	76.4	10.1	915	21	AEJ68509	Aej68509 St repto oco
11	76.4	10.1	915	21	AEJ75484	Aej75484 St repto oco
12	76.4	10.1	915	21	AEJ82844	Aej82844 St repto oco
13	76.4	10.1	915	21	AEL05163	Ael05163 St repto oco
14	76.4	10.1	915	21	AEL12413	Ael12413 St repto oco
15	76.4	10.1	915	21	AEL50821	Ael50821 St repto oco
16	76.4	10.1	915	25	AEM07844	Aem07844 St repto oco
17	76.4	10.1	915	25	AEM66066	Aem66066 St repto oco
18	76.4	10.1	915	25	AEM86645	Aem86645 St repto oco
19	76.4	10.1	915	25	AGI20663	Ag i20663 St repto oco
20	76.4	10.1	915	25	AEN48202	Aen48202 St repto oco
21	76.4	10.1	915	25	AEN55537	Aen55537 St repto oco
22	76.4	10.1	915	25	AEN40434	Aen40434 St repto oco
23	76.4	10.1	915	25	AGI76906	Ag i76906 St repto oco
24	76.4	10.1	915	25	AEN08741	Aen08741 St repto oco
25	76.4	10.1	915	25	AGV09876	Ag v09876 St repto oco
26	76.4	10.1	915	25	AGV21123	Ag v21123 St repto oco
27	76.4	10.1	915	25	AJE78366	Aj e78366 St repto oco
28	76.4	10.1	915	25	AJE70154	Aj e70154 St repto oco
29	76.4	10.1	915	25	AJE86340	Aj e86340 St repto oco
30	76.4	10.1	915	25	AJE95472	Aj e95472 St repto oco
31	76.4	10.1	915	25	AJE61089	Aj e61089 St repto oco
32	76.4	10.1	915	25	AGV40930	Ag v40930 St repto oco
33	76.4	10.1	915	25	AGV46355	Ag v46355 St repto oco
34	76.4	10.1	915	25	AJF01903	Aj f01903 St repto oco
35	76.4	10.1	915	25	AJF07993	Aj f07993 St repto oco
36	76.4	10.1	915	25	AJF13317	Aj f13317 St repto oco
37	76.4	10.1	915	25	AJF53284	Aj f53284 St repto oco
38	76.4	10.1	915	25	AJF18960	Aj f18960 St repto oco
39	76.4	10.1	915	25	AJG97788	Aj g97788 St repto oco
40	76.4	10.1	915	25	ALK14103	Al k14103 S. pneumon
41	76.4	10.1	915	25	ALT08207	Al t08207 St repto oco
42	76.4	10.1	915	25	ANK69294	Ank69294 St repto oco
43	76.4	10.1	915	25	ANJ76477	Anj76477 S. pneumo
44	76.4	10.1	915	25	ANK74634	Ank74634 St repto oco
45	76.4	10.1	915	26	ANN03548	Ann03548 S. pneumo

ALIGMENTS

RESULT 1

AEA00728
 ID AEA00728 standard; DNA; 756 BP.
 XX
 AC AEA00728;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE *Brevibacillus choshi nensis* DNA #1.
 XX
 KW Cell culture; *Brevibacillus choshi nensis*; gene; ds.
 XX
 OS *Brevibacillus choshi nensis*.
 XX
 FH Key Location/Qualifiers
 FT CDS 1..756
 FT /*tag= a
 FT /product = "B. choshi nensis protein #1"
 XX
 PN WO2005045005-A1.
 XX
 PD 19-MAY-2005.
 XX
 PF 08-NOV-2004; 2004WO-JP016912.
 XX
 PR 11-NOV-2003; 2003JP-00381606.
 XX
 PA (HGET) HI GETA SHOYU KK.
 XX
 PI Hanagata H, Nishijyo T;
 XX
 DR WPI ; 2005-366840/37.
 DR P-PSDB; AEA00729.
 XX
 PT New *Brevibacillus choshi nensis*, that does not form spores and which shows low extracellular or intracellular protease activity, useful as host for producing recombinant protein.
 XX
 PS Claim 4; SEQ ID NO 1; 103pp; Japanese.
 XX
 CC The invention relates to a *Brevibacillus choshi nensis* HPD31-SP3 (FERMBP-08479), which does not form spores and which has mycological characteristics such as cell size and rod shape and physiological characteristics such as negative for nitrate reduction and positive for citric acid utilization, oxidase and catalase, and showing low extracellular protease activity. The invention also relates to a transformed *B. choshi nensis* using a vector containing the gene encoding the protein of the invention. *B. choshi nensis* is useful as a host for producing a recombinant protein and for producing a protein by culturing a transformed host. It has decreased extracellular protein degradation activity when compared with other strains. This sequence represents *B. choshi nensis* DNA of the invention.
 XX
 SQ Sequence 756 BP; 207 A; 166 C; 211 G; 172 T; 0 U; 0 Other;
 Query Match 100.0% Score 756; DB 18; Length 756;
 Best Local Similarity 100.0% Pred. No. 3e-234;
 Matches 756; Conservative 0; Missmatches 0; Indels 0; Gaps 0;
 Qy 1 ATGGGTCCCGATATCAAAATGCGAGTCACCATTTCTGACCAATGACCAAGTGAAAGAT 60
 Db 1 ATGGGTCCCGATATCAAAATGCGAGTCACCATTTCTGACCAATGACCAAGTGAAAGAT 60
 Qy 61 TTGATACCCAAGAGCCAAGCTGGCGATACGGATGCACGTGAGCTTCTCGTGAATAGCAAT 120
 Db 61 TTGATACCCAAGAGCCAAGCTGGCGATACGGATGCACGTGAGCTTCTCGTGAATAGCAAT 120
 Qy 121 ATCAGACTGGTCTGGTCCGTCGTCAGCGCTTATCAACCGCGGGTATGAAGCGGATGAT 180
 Db 121 ATCAGACTGGTCTGGTCCGTCGTCAGCGCTTATCAACCGCGGGTATGAAGCGGATGAT 180

Qy	181	TTGTTTCAGATCGGTTGCATTGGCTTGCTCAAGCCCGTTGACAAGTTCGATCTTGTAC 240
Db	181	TTGTTTCAGATCGGTTGCATTGGCTTGCTCAAGCCCGTTGACAAGTTCGATCTTGTAC 240
Qy	241	GATGTGAGATTTGACCTATGCGGTGCCAATGATCATCGGAGAAATTCAACGCTTTTG 300
Db	241	GATGTGAGATTTGACCTATGCGGTGCCAATGATCATCGGAGAAATTCAACGCTTTTG 300
Qy	301	CGCGATGACGGTACGGTTAAGGTCACTCGTTAAAAGAACAGCGATAAGGTGCGG 360
Db	301	CGCGATGACGGTACGGTTAAGGTCACTCGTTAAAAGAACAGCGATAAGGTGCGG 360
Qy	361	CGATCAAAGGATGAATTGACAAGCAATTGGCGGTGCCCCCACGATCGCAGAAGTGGCA 420
Db	361	CGATCAAAGGATGAATTGACAAGCAATTGGCGGTGCCCCCACGATCGCAGAAGTGGCA 420
Qy	421	GAAGCACTGGGAATCA CGCGGGAGGAAGTAGTCTTGCGCAAGAGGCAAGCAGAGGCCT 480
Db	421	GAAGCACTGGGAATCA CGCGGGAGGAAGTAGTCTTGCGCAAGAGGCAAGCAGAGGCCT 480
Qy	481	TCCTCCATCCATGAGACCGTTTTGAAAATGACGGCGATCCATCACACTGATCGATCAG 540
Db	481	TCCTCCATCCATGAGACCGTTTTGAAAATGACGGCGATCCATCACACTGATCGATCAG 540
Qy	541	ATAGCGGATGAAGGTGTGAACAAGTGGTTGAGAAAATTGCCTTGAAGGACGCCATCAGC 600
Db	541	ATAGCGGATGAAGGTGTGAACAAGTGGTTGAGAAAATTGCCTTGAAGGACGCCATCAGC 600
Qy	601	AGGCTGAGCGAGCGT GAGCAGCTCATCGTCTACCTGCGCTATTACAAGGATCAGACACAG 660
Db	601	AGGCTGAGCGAGCGT GAGCAGCTCATCGTCTACCTGCGCTATTACAAGGATCAGACACAG 660
Qy	661	TCTGAGGTAGCAGAGCGTCTAGGGATTTCGCAGGTCCAGGTCTCGGTCTGGAAAAGCGT 720
Db	661	TCTGAGGTAGCAGAGCGTCTAGGGATTTCGCAGGTCCAGGTCTCGGTCTGGAAAAGCGT 720
Qy	721	ATCCTGCTAACGATCAAGGAGCAAATTGAACATTAG 756
Db	721	ATCCTGCTAACGATCAAGGAGCAAATTGAACATTAG 756

RESULT 2

ABK78469

ID ABK78469 standard; DNA; 665 BP.

XX

AC ABK78469;

XX

DT 13- AUG- 2002 (first entry)

XX

DE Bacillus clausii genomic sequence tag (GST) #1312.

XX

KW Differential gene expression; genomic sequenced tag; GST;

KW altered culture condition; environmental stress;

KW physiological provocation; ds.

XX

OS Bacillus clausii.

XX

PN WO200229113-A2.

XX

PD 11- APR- 2002.

XX

PF 05- OCT- 2001; 2001WO-US031437.

XX

PR 06- OCT- 2000; 2000US-00680598.

PR 27- MAR- 2001; 2001US-0279526P.

XX

PA (NOVO) NOVOZYMES BIOTECH INC.

PA (NOVO) NOVOZYMES AS.

XX
 PI Berka R, Clausen I G;
 XX
 DR WPI ; 2002-416684/44.
 XX
 PT Monitoring differential expression of several genes in first *Bacillus* cell relative to expression of same genes in one or more second *Bacillus* cells, by using substrate containing *Bacillus* genomic sequenced tag array.
 XX
 PS Claim 11; SEQ ID NO 5760; 200pp; English.
 XX
 CC The invention describes a method of monitoring differential expression of genes in a first *Bacillus* cell relative to expression of the genes in other *Bacillus* cells, comprising hybridizing labelled nucleic acid probes isolated from *Bacillus* cells to a substrate containing array of *Bacillus* genomic sequenced tags (GST), examining the array, and determining relative gene expression by an observed hybridisation reporter signal of a spot in the array. The method is useful for measuring the expression of genes in a first *Bacillus* cell relative to expression of the same genes in one or more second *Bacillus* cells. The method is useful for monitoring global expression of several genes from a *Bacillus* cell, discovering new genes, identifying possible functions of unknown open reading frames and monitoring gene copy number variation and stability. Monitoring changes in expression of genes may be used to provide a representation of the way in which *Bacillus* cells adapt to changes in culture conditions, environmental stress or other physiological provocation. Extensive follow-up characterisation is unnecessary, when one spot on an array equals one gene or one open reading frame, since sequence information is available. This sequence represents a genomic sequence tag (GST) used in the method of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WPO at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 665 BP; 210 A; 134 C; 159 G; 161 T; 0 U; 1 Other;
 Query Match 36.2% Score 273.4; DB 6; Length 665;
 Best Local Similarity 67.4% Pred. No. 1.9e-77;
 Matches 399; Conservative 0; Mismatches 192; Indels 1; Gaps 1;
 Qy 37 CTGACCAATGACCAAGTGAAGATTGATAGCCAAGAGCCAAGCTGGCATAACGGATGCA 96
 Db 40 CTATCCGATAAACAAAGTGAAGAGCTTATTGCAAAAAGGCCAGGAAGGGACACAGAACAGCA 99
 Qy 97 CGTGAGCTTCCTCGTGAATAGCAATATCAGACTGGCTGGTCGGTCCGGTCAAGGGTTTATC 156
 Db 100 CGGGATTGATCGTCAACCATAACACACAGTCTCGTCTGGTCAGTGGTTAACGTTTTTG 159
 Qy 157 AACCGCGGTATGAACCGGATGATTTGTTTCAAGATCGGTTGCATTGGCTTGCTCAAGGCC 216
 Db 160 AATCGCGGTATGAGCGAGATGACCTTTCAAATTGGCTGATTGGTTAACGTTAACAGTCT 219
 Qy 217 GTTGACAAGTTCGATCTTGTACGATGTGAGATTTGACCTATGCGGTGCAATGATC 276
 Db 220 GTCGACAAATTGACCTTCTACGACGTTGAAATTCCACGATGCTGTGCGATGATT 279
 Qy 277 ATCGGAGAAATTCAACGTTTGGCGATGACGGTAAGGTCAAGTCAAGTGGTCAATGTTA 336
 Db 280 ATTGGTGAAATCCAACGGTTCTGGGGATGATGGCACAGTGAAGTAAGCCGGTCCATT 339
 Qy 337 AAAGAACAGCGAATAAGGTGCGGGCGATCAAAGGATGAATTGACAAGCAATTGGCCGT 396
 Db 340 AAAGAATTAAAGCAATAAAATCCGAAAGCAAAAGACGAACGTGACGAAACGCTGCGCGG 399
 Qy 397 GCCCCCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCACGGGGAGGAAGTAGTCTT 456
 Db 400 GCACCGACCATTAATGAGATCGCTAACATTAGCGTGACGGCTGAGGAAATTGTATTT 459
 Qy 457 GCGCAAGAGGCAAGCAGAGGCGCTTCTCCATCCATGAGACOGTTTTGAAAATGACGGC 516

Db	460	GCTGGAGATGCCAACCGGAGCTTGTCTCAATOCATGAAACGGTTATGAAAATGACGGC	519
Qy	517	GATCCCATCACACTGATCGATCAGATAGCGGATGAAGGTGTGAACAAGTGGTTGAGAAA	576
Db	520	GATCCGATTACACTTCTAGATCAAATTGCCGACCACTCACAAAGTCATAATGGTTGACAAG	579
Qy	577	ATTGCCTTGAAGGAGCOCATCAGCAGGCTGAGGAGCGTGAGCAGCTCATOG	628
Db	580	ATTG CTTTAAAGAAGCGATTGCGACCTTGGCGANAGGGAGCGGCTAATTG	630

RESULT 3

ADN60500

ID ADN60500 standard; DNA; 1438 BP.

XX

AC ADN60500;

XX

DT 01-JUL-2004 (first entry)

XX

DE B. licheniformis sporulation related polynucleotide, seq id 172.

XX

KW Mutant host cell; sporulation; oxidoreductase; transferase; hydrolase;

KW lyase; isomerase; ligase; gene; ds.

XX

OS Bacillus licheniformis.

XX

PN WO2003087148-A2.

XX

PD 23-OCT-2003.

XX

PF 25-MAR-2003; 2003WO-DK000200.

XX

PR 10-APR-2002; 2002DK-00000533.

XX

PA (NOVO) NOVOZYMES AS.

XX

PI Andersen JT, Jorgensen ST, Rasmussen MD, Aasen PB, Gausen IG;

XX

DR WPI ; 2004-122131/12.

DR P-PSDB; ADN60501.

XX

PT A Bacillus licheniformis mutant host cell for producing a product of interest e.g. vitamins, antibiotics and enzymes.

XX

PS Claim 1; SEQ ID NO 172; 319pp; English.

XX

CC The invention relates to a *Bacillus licheniformis* mutant host cell derived from a parent *B. licheniformis* host cell. The mutant host cell is mutated in one or more genes encoding one or more polypeptides involved in sporulation. The host cell comprises one or more heterologous genes present in at least two copies, encoding one or more heterologous polypeptides. The heterologous genes are stably integrated into the genome of the cell without leaving any antibiotic resistance marker genes at the site of integration. The heterologous genes are transcribed from a heterologous promoter or from an artificial promoter, and are comprised in an operon, preferably a polycistronic operon. The heterologous polypeptide is an antimicrobial peptide, or a fusion peptide comprising a peptide part which in its native form has antimicrobial activity. The heterologous polypeptide is an enzyme, preferably a secreted enzyme. The enzyme is an enzyme of a class selected from the group of enzyme classes consisting of oxidoreductases (EC 1), transferases (EC 2), hydrolases (EC 3), lyases (EC 4), isomerases (EC 5), and ligases (EC 6). The *Bacillus licheniformis* is useful in a process for producing at least one product of interest, comprising cultivating a *B. licheniformis* mutant host cell in a suitable medium whereby the said product is produced. The process further comprises isolating or purifying the product of interest. The current sequence represents a *B. licheniformis* sporulation related polynucleotide.

XX
 SQ Sequence 1438 BP; 421 A; 324 C; 355 G; 338 T; 0 U; 0 Other;
 Query Match 25.4% Score 192.2; DB 12; Length 1438;
 Best Local Similarity 63.7% Pred. No. 7.1e-51;
 Matches 309; Conservative 0; Mismatches 173; Indels 3; Gaps 1;

Qy 1 ATGGGTCCGATATCAAAATGCGAGTCACCATTTCTGACCAATGACC--AAGTGAAA 57
 Db 954 ATGGATGTGGAGGTTAAAAAGAAAACAGAACACTCAGCTTAAAGACCATGAAGTGAAA 1013

Qy 58 GATTTGATAGCCAAGAGCCAAGCTGGCGATACGGATGCACGTGAGCTTCTCGTGAATAGC 117
 Db 1014 GAACTGATTAAAAACAGCCAGAACGGCGATCAAAAGCAAGGGACCTCCTCATAGAAAAA 1073

Qy 118 AATATCAGACTGGTCTGGTCCGTCGTCCAGCGCTTATCAAAACGGGGTATGAAGGGAT 177
 Db 1074 AACATCCGTCTTGGTCTGCGTCAGCGTTTTGAACAGAGGCTATGAGCCTGAC 1133

Qy 178 GATTTGTTTCAGATCGGTTGCATTGGCTGCTCAAGGCGGTGACAAGTCGATCTTCG 237
 Db 1134 GACCTCTTCAAATCGGTCGATCGGCTCTTGAAGTCGGTGGACAAATCGATCTTC 1193

Qy 238 TACGATGTGAGATTTCGACCTATGGGTGCCATGATCGGAGAAATTCAACGCTTT 297
 Db 1194 TATGACGTTGGTTTCCACCTACGCCGTCGATGATTATGGCGAGATTAGCGGTTT 1253

Qy 298 TTGCGCGATGACGGTACGGTAAGTCAGTCGATCGTTAAAGAAACAGCGAATAAGGTG 357
 Db 1254 ATCAGAGATGACGGAACCGTCAAAGTGAGCCGCTCGCTGAAAGAACTCGGCAACAAATC 1313

Qy 358 CGGCGATCAAAGGATGAATTGACAAGCAATTGGCGTGCACCGATCGCAGAAGTG 417
 Db 1314 CGGCGGGCGAAAGACGAGCTTCCAAGTCAAACGGCGGATTCCGACCGTTAGGAAATC 1373

Qy 418 GCAGAACCGAGTGGATCAAGCCGGAGGAAGTAGTCCTTGGCAAGAGGCAACGAGCG 477
 Db 1374 GCCGATTATCTCGAAATCAGTTAGAAAGAGGTGATGGCCCAGGAAGGGTCCGCTCT 1433

Qy 478 CCTTC 482
 Db 1434 CCCTC 1438

RESULT 4

AEH93992

ID AEH93992 standard; cDNA; 777 BP.

XX AC AEH93992;

XX

DT 27-JUL-2006 (first entry)

XX

DE Sigma coding sequence.

XX

KW ss; gene; protein product ion; sigma factor; RNA polymerase;

KW alkaline protease; food.

XX

OS Bacillus sp.; KSM 9865.

XX

FH Key Location/Qualifiers

FT CDS 1..777

FT /*tag= a

FT /product= "Sigma"

XX

PN JP2006136221-A.

XX

PD 01-JUN-2006.

XX

PF 10-NOV-2004; 2004JP-00326973.

XX
 PR 10- NOV- 2004; 2004JP- 00326973.
 XX
 PA (KAOS) KAO CORP.
 XX
 PI Sumitomo N, Okuda T, Takimura Y, Satoh T, Kobayashi T;
 XX
 DR WPI ; 2006- 385028/ 40.
 DR P- PSDB; AEH93994.
 XX
 PT Novel sporulation related gene encoding SigE protein or SigG protein
 PT having alkaline protease activity, useful in foodstuffs such as alcoholic
 PT beverage, bean paste, soy sauce, pharmaceuticals and cosmetics.
 XX
 PS Claim 1; SEQ ID NO 2; 15pp; Japanese.
 XX
 CC This sequence represents the SigG sequence which encodes the sigma factor
 CC which is a subunit of RNA polymerase. A microorganism transformed with
 CC the SigE or SigG sequence is useful for producing a protein or
 CC polypeptide having alkaline protease activity. The sigma peptides are
 CC useful in foodstuffs e.g. alcoholic beverage, bean paste, soy sauce,
 CC pharmaceuticals and cosmetics. The protein having alkaline protease
 CC activity can be produced efficiently using non-sporulated microorganisms.
 XX
 SQ Sequence 777 BP; 264 A; 123 C; 189 G; 201 T; 0 U; 0 Other;
 Query Match 23.6% Score 178.2; DB 21; Length 777;
 Best Local Similarity 53.9% Pred. No. 1.8e-46;
 Matches 391; Conservative 0; Missmatches 328; Indels 6; Gaps 1;

```

Qy      31 CCATTCTGACCAATGCCAAGTGAAGAGATTGATAGCCAAAGGCCAACGCTGGCGATACG 90
Db      49 CCTGTTTGAAAGATGAAGAAATGCCAACGTTATTCTGTAAATGCCAGGGCGAGAACTT 108
Qy      91 GATGCCACGTGAGCTTCTCGTGAATAGCAATATCAGACTGGCTGGTOCGTCGTCCAGCGC 150
Db      109 TCTGCAAGAGAAAAGCTCGTGAATGCCAACCAAAGGCTGTTCTAAGTGTATTCAACGG 168
Qy      151 TTTATCAAACCGGGGTATGAAGCGGATGATTGTTAGATGGCTGGCTGGCTGGCTGGCTC 210
Db      169 TTTAACAAACCGTGGTGAATTGAGATGACTTATTCAAGTAGGCTGCATGGTTAATG 228
Qy      211 AAGGCCGTTGACAAGTTCGATCTTCGATACGATGTGAGATTTCGACCTATGCCGGGCC 270
Db      229 AAGTCGATTGATAATTGACCTGGCTCAGATGTTAAGTTCTACATATGCCAGTACCA 288
Qy      271 ATGATCATCGGAGAAATTCAACGCTTTGGCGGATGACGGTACGGTAAGGTCACTCGA 330
Db      289 ATGATAATCGGGGAGATAAGGGCGTATCTACGAGATAATAATCCGATCAGGGTATCCGC 348
Qy      331 TCGTTAAAAGAAACAGCGAATAAGGTGGGGGATCAAAGGTGAATTGTACAAGCAATT 390
Db      349 TCATTGGGTGATATTGCCTACAAGGCCCTGCAGGTAGGGAAAGGCTGATGAGTGAACACA 408
Qy      391 GGCGCGTCCCCCACGATCGCAGAAGTGGCAGAACCGAGTGGGAATCACGCCGGAGGAAGTA 450
Db      409 TCAAGGGAGGCTACCGCAGAAGAAATTCAAAAGTACTTGAAGTACCGATGAGGAGATT 468
Qy      451 GTCTTGGCAAGAGGCAAGCAGAGCGCTTCCCATCCATGAGACCGTTTTGAAAAT 510
Db      469 GTTTTGGCTTAAATGCTATTCAAGGATCCGTTGTCCTTATTGAGCCTATCTATAATGAT 528
Qy      511 GACGGCGATCCCATCACACTGATCGATCAGATAGCGGATGAAGGTGTGAA-----CAAG 564
Db      529 GGTGGAGATCCGATTATGTTGGATCAAATCAGTGACGAAAAGAACAAAGATATCCAA 588
Qy      565 TGGTTGAGAAAATTGCCTGAAGGACGCCATCAGCAGGCTGAGCGAGCGTGAGCAGCTC 624
Db      589 TGGATAGAAGAGATAGCACTAAAAGAAGGTATGAGACGTCTCAATGACAGGAAAAGCTC 648

```

Qy	625 ATCGTCTAOCCTGGCTATTACAAGGATCAGACACAGTCTGAGGTAGCAGAGCGTAGGG 684
Db	649 ATTTTAAGAAAACGGTTTTCAAGGAAAACGCAAATGGAAGTAGCTGATGAAATCGGG 708
Qy	685 ATTCGCCAGGTCCAGGTCTCGCGTCTGGAAAAGCGTATCCTGCTAACGATCAAGGAGCAA 744
Db	709 ATATGCCAAGCACAAAGTGTCAAGACTTGAAAAGCCTGCAATCAAACAGATGAATAAAAT 768
Qy	745 ATTGA 749
Db	769 ATTCA 773

RESULT 5

ABK74144

ID ABK74144 standard; DNA; 381 BP.

XX

AC ABK74144;

XX

DT 13-AUG-2002 (first entry)

XX

DE Bacillus licheniformis genomic sequence tag (GST) #1435.

XX

KW Differential gene expression; genomic sequenced tag; GST;

KW altered culture condition; environmental stress;

KW physiological provocation; ds.

XX

CS Bacillus licheniformis.

XX

PN WO200229113-A2.

XX

PD 11-APR-2002.

XX

PF 05-OCT-2001; 2001WO-US031437.

XX

PR 06-OCT-2000; 2000US-00680598.

PR 27-MAR-2001; 2001US-0279526P.

XX

PA (NOVO) NOVOZYMES BIOTECH INC.

PA (NOVO) NOVOZYMES AS.

XX

PI Berka R, Clausen IG;

XX

DR WPI ; 2002-416684/44.

XX

PT Monitoring differential expression of several genes in first Bacillus cell relative to expression of same genes in one or more second Bacillus cells, by using substrate containing Bacillus genomic sequenced tag array.

XX

PS Claim 4; SEQ ID NO 1435; 200pp; English.

XX

CC The invention describes a method of monitoring differential expression of genes in a first Bacillus cell relative to expression of the genes in other Bacillus cells, comprising hybridizing labelled nucleic acid probes isolated from Bacillus cells to a substrate containing array of Bacillus genomic sequenced tags (GST), examining the array, and determining relative gene expression by an observed hybridization reporter signal of a spot in the array. The method is useful for measuring the expression of genes in a first Bacillus cell relative to expression of the same genes in one or more second Bacillus cells. The method is useful for monitoring global expression of several genes from a Bacillus cell, discovering new genes, identifying possible functions of unknown open reading frames and monitoring gene copy number variation and stability. Monitoring changes in expression of genes may be used to provide a representation of the way in which Bacillus cells adapt to changes in culture conditions, environmental stress or other physiological provocation. Extensive follow-up characterisation is unnecessary, when one spot on an array equals one

CC gene or one open reading frame, since sequence information is available.
 CC This sequence represents a genomic sequence tag (GST) used in the method
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from WPO at ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 381 BP; 109 A; 91 C; 94 G; 87 T; 0 U; 0 Other;

Query Match 23.0% Score 173.8; DB 6; Length 381;
 Best Local Similarity 66.9% Pred. No. 3.4e-45;
 Matches 247; Conservative 0; Mismatches 122; Indels 0; Gaps 0;

Qy	50	AAGTGAAGAGATTGATAGCCAAGAGCCAAGCTGGCGATACGGATGCACGTGAGCTTCCTCG	109
Db	13	AAGTGAAGAGAACTGATTAAAAACAGCCAGAACGCCATCAAAAAGCAAGGGACCTCCTCA	72
Qy	110	TGAATAGCAATATCAGACTGGTCTGGCOGTCGTCAGCGCTTATCAACCGCGGGTATG	169
Db	73	TAGAAAAAAACATGGCTTGTGTTGGTCTGCGTTAGCGTTTTTGAAACAGAGGCTATG	132
Qy	170	AAGCGGATGATTGTTTCAAGATGGTGCATTGGCTTGCCTAAGCGCGTTGACAAGTTG	229
Db	133	AGCCTGACGACCTCTTCAAATCGGCTGCATCGGCCCTTGAAGTCGGTGGACAAATTG	192
Qy	230	ATCTTTOGTACGATGTGAGATTTGAGACCTATGGGTGCGAATGATCATCGGAGAAATTG	289
Db	193	ATCTTTCCTATGACGTTGGTTTCCACCTACGCCGTTGGATGATTATGGCGAGATTG	252
Qy	290	AACGCTTTTGCAGATGAAGGTACGGTAAGGTCAAGTCAGTCGATCGTTAAAGAAACAGCGA	349
Db	253	AGCGGTTATCAGAGATGAAGAACCGTCAAAGTGAGCGCTCGCTGAAAGAACTCGGCA	312
Qy	350	ATAAGGTGGGGATCAAAGGTGAATTGATCAAGCAATTGGCGTGGCCCCAACGATCG	409
Db	313	ACAAAATCGGCGGGCGAAAGACGAGCTTCCAAGTCAAACGGCGGATTCCGACOGTTC	372
Qy	410	CAGAAGTGG	418
Db	373	AGGAAATCG	381

RESULT 6

ABK74048

ID ABK74048 standard; DNA; 631 BP.

XX
 AC ABK74048;

XX
 DT 13-AUG-2002 (first entry)

XX
 DE *Bacillus licheniformis* genomic sequence tag (GST) #1339.

XX
 KW Differential gene expression; genomic sequenced tag; GST;
 KW altered culture condition; environmental stress;
 KW physiological provocation; ds.

XX
 OS *Bacillus licheniformis*.

XX
 PN WO200229113-A2.

XX
 PD 11-APR-2002.

XX
 PF 05-OCT-2001; 2001WO-US031437.

XX
 PR 06-OCT-2000; 2000US-00680598.
 PR 27-MAR-2001; 2001US-0279526P.

XX
 PA (NOVO) NOVOZYMES BIOTECH INC.
 PA (NOVO) NOVOZYMES AS.

PI Berka R, Clausen LG;
 XX
 DR WPI ; 2002-416684/44.
 XX
 PT Monitoring differential expression of several genes in first *Bacillus* cell relative to expression of same genes in one or more second *Bacillus* cells, by using substrate containing *Bacillus* genomic sequenced tag array.
 XX
 PS Claim 4; SEQ ID NO 1339; 200pp; English.
 XX
 CC The invention describes a method of monitoring differential expression of genes in a first *Bacillus* cell relative to expression of the genes in other *Bacillus* cells, comprising hybridising labelled nucleic acid probes isolated from *Bacillus* cells to a substrate containing array of *Bacillus* genomic sequenced tags (GST), examining the array, and determining relative gene expression by an observed hybridisation reporter signal of a spot in the array. The method is useful for measuring the expression of genes in a first *Bacillus* cell relative to expression of the same genes in one or more second *Bacillus* cells. The method is useful for monitoring global expression of several genes from a *Bacillus* cell, discovering new genes, identifying possible functions of unknown open reading frames and monitoring gene copy number variation and stability. Monitoring changes in expression of genes may be used to provide a representation of the way in which *Bacillus* cells adapt to changes in culture conditions, environmental stress or other physiological provocation. Extensive follow-up characterisation is unnecessary, when one spot on an array equals one gene or one open reading frame, since sequence information is available. This sequence represents a genomic sequence tag (GST) used in the method of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WPO at ftp://wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 631 BP; 203 A; 121 C; 161 G; 146 T; 0 U; 0 Other;
 Query Match 19.4% Score 147; DB 6; Length 631;
 Best Local Similarity 56.8% Pred. No. 2.3e-36;
 Matches 270; Conservative 0; Mismatches 205; Indels 0; Gaps 0;

```

Qy      77 AAGCTGGCGATACGGATGCACGTGAGCTTCTCGTGAATAGCAATATCAGACTGGCTGGT 136
Db      98 ATGAAGGAGACACAACAGCGAGAGAAAAGCTTGTAAACGGCAATTGCGCCCTTGTCTTAA 157
Qy      137 CCGTCGTCAGCGCTTTATCAACCGCGGGTATGAAGCGGATGATTGTTTCAGATCGGTT 196
Db      158 GCGTCATTCAAAGGTTAACAAACAGAGGGAGAATATGTTGATGACTTATTCCAAGTCGGCT 217
Qy      197 GCATTGGCTTGCTCAAGGCGTTGACAAGTTGATCTTCGTACGATGTGAGATTTCGA 256
Db      218 GCATCGGACTAATGAAATCAATTGATAATTGACCTGAGCCACAATGTTAAGTTCAA 277
Qy      257 CCTATCGGGTGCCTAATGATCATCGGAGAAATTCAACGCTTTGCGCGATGACGGTACGG 316
Db      278 CATATGCTGTACCAATGATCATCGGAGAAATCGCAGATATTGCGCGATAACAAACCGA 337
Qy      317 TTAAGGTCACTCGATCGTTAAAGAAACAGCGAATAAGGTGCGCGATCAAAGGATGAAT 376
Db      338 TCCCGCTCTCACGGTCACTCAGGGATATCGCGTACAAGGGCGTCCAAGTGAGAGAACGGC 397
Qy      377 TGTACAAGCAATTGGCGTGCCTTACCGATCGCAGAAGTGGCAGAAGCAGTGGAAATCA 436
Db      398 TGATCAGTGAGACAAGCAGGGAGCGACTGCTCAGGAGATCGCTAAAGAGCTTGAAGTGT 457
Qy      437 CGCGCGAGGAAGTAGTCTTGGCAAGAGGCAAGCAGAGCCCTTCCCTCATCCATGAGA 496
Db      458 CCCATGAAGAAATCGTTTGGCTTGACGCCATTCAAGATCCTGTATCTTGTGGAC 517
Qy      497 CGGTTTTGAAAATGACGGCGATCCCATCACACTGATCGATCAGATAGCGGATGA 551
    
```

Db 518 CGATTACAAATGAOGGAGGAGATCGATTATGTCATGGATCAAATCAGCGATGA 572

RESULT 7

ADH97013

ID ADH97013 standard; DNA; 1110 BP.

XX

AC ADH97013;

XX

DT 06-MAY-2004 (first entry)

XX

DE S. pneumoniae RNA polymerase sigma-70 factor gene #2.

XX

KW anti bacterial; anti inflammatory; gastrointestinal; anti ulcer;

KW anti diarrhoeic; opthalmological; enzyme inhibitor; antisense therapy;

KW vaccine; microbial target; modulator; furuncle; pneumonia; gastritis;

KW peptic ulcer disease; diarrhoea; meningitis; bacteraemia; conjunctivitis;

KW toxic shock syndrome; gene; ds.

XX

OS Streptococcus pneumoniae.

XX

PN WO2003102190-A2.

XX

PD 11-DEC-2003.

XX

PF 02-JUN-2003; 2003WO-CA000786.

XX

PR 31-MAY-2002; 2002US-0384634P.

PR 31-MAY-2002; 2002US-0385157P.

PR 04-JUN-2002; 2002US-0385542P.

PR 04-JUN-2002; 2002US-0385611P.

PR 04-JUN-2002; 2002US-0385747P.

PR 04-JUN-2002; 2002US-0385750P.

PR 04-JUN-2002; 2002US-0385752P.

PR 04-JUN-2002; 2002US-0385773P.

PR 04-JUN-2002; 2002US-0385780P.

PR 04-JUN-2002; 2002US-0385785P.

PR 04-JUN-2002; 2002US-0385797P.

PR 05-JUN-2002; 2002US-0385962P.

PR 05-JUN-2002; 2002US-0386022P.

PR 05-JUN-2002; 2002US-0386024P.

PR 05-JUN-2002; 2002US-0386087P.

PR 05-JUN-2002; 2002US-0386141P.

PR 05-JUN-2002; 2002US-0386350P.

PR 05-JUN-2002; 2002US-0386586P.

PR 06-JUN-2002; 2002US-0386368P.

PR 06-JUN-2002; 2002US-0386369P.

PR 06-JUN-2002; 2002US-0386436P.

PR 06-JUN-2002; 2002US-0386441P.

PR 06-JUN-2002; 2002US-0386528P.

PR 06-JUN-2002; 2002US-0386573P.

PR 06-JUN-2002; 2002US-0386834P.

PR 31-JUL-2002; 2002US-0399839P.

PR 31-JUL-2002; 2002US-0399861P.

PR 31-JUL-2002; 2002US-0399969P.

PR 31-JUL-2002; 2002US-0399970P.

PR 31-JUL-2002; 2002US-0399983P.

PR 31-JUL-2002; 2002US-0399984P.

PR 31-JUL-2002; 2002US-0399985P.

PR 01-AUG-2002; 2002US-0400154P.

PR 01-AUG-2002; 2002US-0400230P.

PR 01-AUG-2002; 2002US-0400268P.

PR 01-AUG-2002; 2002US-0400363P.

PR 01-AUG-2002; 2002US-0400365P.

PR 01-AUG-2002; 2002US-0400374P.

PR 01-AUG-2002; 2002US-0400380P.

PR 01-AUG-2002; 2002US-0400433P.

PR 01-AUG-2002; 2002US-0400434P.

PR 01-AUG-2002; 2002US-0400436P.

PR 01- AUG 2002; 2002US-0400442P.
 PR 01- AUG 2002; 2002US-0400463P.
 XX
 PA (AFFI -) AFFI NI UM PHARM I NC.
 XX
 PI Edwar ds A, Dhar amsi A, Vedadi M, Val lee F, Awrey D, Beattie B;
 PI Ri char ds D, Domagal a M, Mansour y K, Vir ag C, Buzadzi ja K;
 PI Mcdonal d M, Houston S, Ar rowsmith C, Ouyang H, Net her y K, Ng I ;
 PI Kanagar aj ah D;
 XX
 DR WPI ; 2004-071165/ 07.
 DR P- PSDB; ADH97014.
 XX
 PT Compositions comprising recombinant polypeptide targets for pathogenic bacteria, useful for designing modulators for preventing or treating a disease or disorder associated with the species of origin for the polypeptide.
 PT
 PS Claim 23; SEQ ID NO 204; 606pp; English.
 XX
 CC The invention relates to novel compositions (1) comprising isolated, recombinant polypeptides, amino acid sequences having at least about 95% identity with these or an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of the polynucleotide encoding these polypeptides. The compositions and polypeptides are useful as microbial targets for designing modulators for the prevention or treatment of a disease or disorder associated with the species of origin for the polypeptide, e.g. furuncle, pneumonia, gastritis, peptic ulcer disease, diarrhoea, meningitis, bacteraemia, conjunctivitis or toxic shock syndrome. The polypeptides are also useful for diagnosing a patient suffering from a disease or disorder of a pathogenic species, or for monitoring the effectiveness of an anti-pathogenic treatment. This sequence corresponds to one of the DNA sequences of the invention
 XX
 SQ Sequence 1110 BP; 341 A; 211 C; 267 G; 291 T; 0 U; 0 Other;
 Query Match 10.3% Score 78; DB 12; Length 1110;
 Best Local Similarity 50.7% Pred. No. 8.1e-14;
 Matches 214; Conservative 0; Missmatches 205; Indels 3; Gaps 1;

```

Qy      31 CCATTCTGACCAATGACCAAGTGAAGAGATTGATGCCAAGAGCCAAGCTGGCGATACG 90
Db      328 CCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGCCACTGGCTGTTGAAGCTGGT GATATC 387
Qy      91 GATGCACGTGAGCTTCTCGTGAATAGCAATATCAGACTGGCTGGTCCGTCGTCAGCGC 150
Db      388 GAAGCCAAACAAACGCTTGGGAACGCAATCTCGTTGGTTGTTCCATTGCCAACGC 447
Qy      151 TTTATCAAACCGGGGATGAAGGGATGATTGTTAGATGGTTGCATTGGCTTGCTC 210
Db      448 TATGTCGGTGGCATGCAGTTCTTGACTTCAAGAAGGAAATATGGCTTGATG 507
Qy      211 AAGGCCGTTGACAAGTTCGATCTTCGTACGATGTGAGATTTCGACCTATGGGTGCCA 270
Db      508 AAGGCCGTTGACAAGTTGACTATTCTAAAGGGTCAAGTTCAACTTATGCAACTTGG 567
Qy      271 ATGATCATCGGAGAAAT---TCAACGTTTTGCGCGATGACGGTACGGTTAAGGTCACT 327
Db      568 TGGATTCTGTCAGGCTATCACTCGTCTTGGGACCAAGCTCGTACCATCCGTATCCC 627
Qy      328 CGATCGTTAAAAGAAACAGCGAATAAGGTGCGGGCGATCAAAGGATGAATTGTACAAGCAA 387
Db      628 GTTCACATGGTGAAGACTATCAATAATTGGTTGCTGAACAGCGGAATCTCCTCAAGAA 687
Qy      388 TTCCGGCCGTGCCCGCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCACGCCGGAGGAA 447
Db      688 TTGGGGCAAGATCGACACCCAGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG 747

```

Qy 448 GT 449
||
Db 748 GT 749

RESULT 8

AEC13368

ID AEC13368 standard; DNA; 1110 BP.

XX

AC AEC13368;

XX

DT 20-OCT-2005 (first entry)

XX

DE Streptococcus pneumoniae RNA polymerase sigma-70 factor gene.

XX

KW protein purification; antibacterial; antimicrobial; infection;

KW drug screening; RNA polymerase sigma-70 factor; gene; ss.

XX

OS Streptococcus pneumoniae.

XX

PN US2005181464-A1.

XX

PD 18-AUG-2005.

XX

PF 29-SEP-2004; 2004US-00953901.

XX

PR 04-APR-2002; 2002US-0369819P.

PR 04-APR-2002; 2002US-0369826P.

PR 04-APR-2002; 2002US-0369831P.

PR 04-APR-2002; 2002US-0370060P.

PR 08-APR-2002; 2002US-0370681P.

PR 08-APR-2002; 2002US-0370806P.

PR 08-APR-2002; 2002US-0370852P.

PR 08-APR-2002; 2002US-0370868P.

PR 09-APR-2002; 2002US-0370959P.

PR 09-APR-2002; 2002US-0370978P.

PR 09-APR-2002; 2002US-0371008P.

PR 09-APR-2002; 2002US-0371009P.

PR 09-APR-2002; 2002US-0371014P.

PR 09-APR-2002; 2002US-0371025P.

PR 09-APR-2002; 2002US-0371064P.

PR 09-APR-2002; 2002US-0371065P.

PR 09-APR-2002; 2002US-0371094P.

PR 09-APR-2002; 2002US-0371114P.

PR 09-APR-2002; 2002US-0371180P.

PR 09-APR-2002; 2002US-0371189P.

PR 31-MAY-2002; 2002US-0384634P.

PR 31-MAY-2002; 2002US-0385157P.

PR 04-JUN-2002; 2002US-0385542P.

PR 04-JUN-2002; 2002US-0385611P.

PR 04-JUN-2002; 2002US-0385747P.

PR 04-JUN-2002; 2002US-0385750P.

PR 04-JUN-2002; 2002US-0385752P.

PR 04-JUN-2002; 2002US-0385773P.

PR 04-JUN-2002; 2002US-0385780P.

PR 04-JUN-2002; 2002US-0385785P.

PR 04-JUN-2002; 2002US-0385797P.

PR 05-JUN-2002; 2002US-0385962P.

PR 05-JUN-2002; 2002US-0386022P.

PR 05-JUN-2002; 2002US-0386024P.

PR 05-JUN-2002; 2002US-0386087P.

PR 05-JUN-2002; 2002US-0386141P.

PR 05-JUN-2002; 2002US-0386350P.

PR 05-JUN-2002; 2002US-0386586P.

PR 06-JUN-2002; 2002US-0386368P.

PR 06-JUN-2002; 2002US-0386369P.

PR 06-JUN-2002; 2002US-0386436P.

PR 06-JUN-2002; 2002US-0386441P.

PR 06-JUN-2002; 2002US-0386528P.

PR 06- JUN- 2002; 2002US- 0386573P.
 PR 06- JUN- 2002; 2002US- 0386834P.
 PR 31- JUL- 2002; 2002US- 0399839P.
 PR 31- JUL- 2002; 2002US- 0399861P.
 PR 31- JUL- 2002; 2002US- 0399969P.
 PR 31- JUL- 2002; 2002US- 0399970P.
 PR 31- JUL- 2002; 2002US- 0399983P.
 PR 31- JUL- 2002; 2002US- 0399984P.
 PR 31- JUL- 2002; 2002US- 0399985P.
 PR 01- AUG- 2002; 2002US- 0400154P.
 PR 01- AUG- 2002; 2002US- 0400230P.
 PR 01- AUG- 2002; 2002US- 0400268P.
 PR 01- AUG- 2002; 2002US- 0400363P.
 PR 01- AUG- 2002; 2002US- 0400365P.
 PR 01- AUG- 2002; 2002US- 0400374P.
 PR 01- AUG- 2002; 2002US- 0400380P.
 PR 01- AUG- 2002; 2002US- 0400433P.
 PR 01- AUG- 2002; 2002US- 0400434P.
 PR 01- AUG- 2002; 2002US- 0400436P.
 PR 01- AUG- 2002; 2002US- 0400442P.
 PR 01- AUG- 2002; 2002US- 0400463P.
 PR 04- APR- 2003; 2003WO- CA000465.
 PR 08- APR- 2003; 2003WO- CA000482.
 PR 08- APR- 2003; 2003WO- CA000483.
 PR 02- JUN- 2003; 2003WO- CA000786.

XX

PA (AFFI -) AFFI NI UM PHARM I NC.

XX

PI Edwards A, Dharansi A, Vedadi M, Alam MZ, Arrowsmith C, Awrey DE;
 PI Beattie B, Budzdzija K, Clarke T, Domagala M, Houston S;
 PI Kanagarajah D, Li Q, Mansoury K, McDonald M, Netherby-Brook K, Ng I;
 PI Ouyang H, Richards D, Vallee F, Virag C;

XX

DR WPI ; 2005- 628190/ 64.

DR P- PSDB; AEC13369.

XX

PT Novel crystallized, recombinant bacterial polypeptide, useful as targets
 PT for pathogenic bacteria such as Helicobacter pylori, Staphylococcus
 PT aureus, for detecting pathogenic species in biological sample, and in
 PT drug designing.

XX

PS Claim 85; SEQ ID NO 204; 637pp; English.

XX

CC The invention relates to a composition (1) comprising purified
 CC polypeptides from bacteria. Also described: (1) a crystallized,
 CC recombinant polypeptide comprising an amino acid sequence of (1), where
 CC the polypeptide is in crystal form; (2) a crystallized complex comprising
 CC the crystallized, recombinant polypeptide and a co-factor or a small
 CC organic molecule, where the complex is in crystal form; and (3) a host
 CC cell comprising a nucleic acid encoding a polypeptide of (1), where a
 CC culture of the host cell produces at least about 1 mg of the polypeptide
 CC per liter of culture and the polypeptide is at least about one-third
 CC soluble as measured by gel electrophoresis. (1) can be used as a target
 CC for pathogenic bacteria, useful for detecting the presence of a
 CC pathogenic species in a biological sample. (1) is useful for monitoring
 CC the effectiveness of anti-pathogenic treatments in an individual
 CC suffering from a disease or disorder caused by a pathogenic bacteria,
 CC such as infections. (1) is also useful in drug design and screening, for
 CC identifying inhibitors of (1), for designing a potential compound that is
 CC useful for treating or preventing pathogenic diseases or disorders, for
 CC assessing the activity of small molecules and other modulators in an
 CC vitro assay, and for developing antimicrobial agents. The present
 CC sequence represents a Streptococcus pneumoniae RNA polymerase sigma-70
 CC factor gene, which is used in an example from the present invention.

XX

SQ Sequence 1110 BP; 341 A; 211 C; 267 G; 291 T; 0 U; 0 Other;

Query Match 10.3% Score 78; DB 18; Length 1110;
 Best Local Similarity 50.7% Pred. No. 8.1e- 14;

Matches 214; Conservative 0; Mismatches 205; Indels 3; Gaps 1;

```

Qy      31 CCATTCTGACCAATGACCAAGTGAAGAGATTGATGCCAAGAGCCAAAGCTGGGATACG 90
Db      328 CCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGCCACTGGCTGTTGAAGCTGGTATATC 387
Qy      91 GATGACCGTGAGCTCTCGTGAATAGCAATATCAGACTGGCTGGTCCGTGTCAGCGC 150
Db      388 GAAGCCAAACAACGTCCTGGGAACCAATCTCGTTGGTTCCATTGCCAACCGC 447
Qy      151 TTTATCAACCGCGGGTATGAAGCGGATGATTGTTCAGATCGGTTGCATTGGCTTGCTC 210
Db      448 TATGTCGGTCGTGGCATGCAGTCCCTGACTTGATTCAAGAAGGAAATATGGGCTTGATG 507
Qy      211 AAGGCCGTTGACAAGTCGATCTTCGTACGATGTGAGATTTCGACCTATGGGTGCCA 270
Db      508 AAGGCCGTTGACAAGTTGACTATTCAAAGGGTCAAGTTCAACTTATGCAACTTGG 567
Qy      271 ATGATCATCGGAGAAAT- - TCAACGCTTTTGCGCGATGACGGTACGGTTAAGGTCAGT 327
Db      568 TGGATTCGTCAGGCTATCACTCGTCTATTGGGACCAAGCTCGTACCATCGTATCCCA 627
Qy      328 CGATCGTAAAAGAAACAGCGATAAGGTGCCCGATCAAAGGATGAATTGTACAAGCAA 387
Db      628 GTTCACATGGTGAAGACTATCAATAAATTGGTTCGTGAACAGCGGAATCTCCTCAAGAA 687
Qy      388 TTGGCGCGTCCCCCACGATCGCAGAAGTGGCAGAAGCAGTGGAAATCAOGCGGGAGGA 447
Db      688 TTGGGCCAAGATCGACACAGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG 747
Qy      448 GT 449
Db      748 GT 749

```

RESULT 9

ADK44581

ID ADK44581 standard; DNA; 915 BP.

XX

AC ADK44581;

XX

DT 24-FEB-2005 (first entry)

XX

DE Streptococcus pneumoniae gene, Seq ID No 1096.

XX

KW ds; gene; Antibacterial; Gene therapy; Vaccine; Streptococcus pneumoniae.

XX

OS Streptococcus pneumoniae.

XX

PN US6699703-B1.

XX

PD 02-MAR-2004.

XX

PF 26-MAY-2000; 2000US-00583110.

XX

PR 02-JUL-1997; 97US-0051553P.

PR 12-MAY-1998; 98US-0085131P.

PR 30-JUN-1998; 98US-00107433.

XX

PA (GENO-) GENOME THERAPEUTICS CORP.

XX

PI Doucette-Stramm L, Bush D, Zeng Q, Opperman T, Housewright CE;

XX

DR WPI; 2004-212399/20.

DR P-PSDB; ADK47242.

XX

PT New nucleic acid molecules and polypeptides useful for diagnosing, preventing and treating pathological conditions resulting from bacterial infection, e.g. Streptococcus pneumoniae infection, and in drug

PT

PT

PT

PT screeni ng.

XX

PS Disclosure; SEQ ID NO 1096; 301pp; Engl i sh.

XX

CC The invention relates to isolated Streptococcus pneumoniae nucleic acids
 CC and polypeptides. The nucleic acids and proteins are useful for
 CC diagnosing, preventing and treating pathological conditions resulting
 CC from bacterial infection, such as S. pneumoniae infection. These may also
 CC be used for drug screening procedures. The present sequence represents a
 CC Streptococcus pneumoniae nucleic acid of the invention. Note: The
 CC sequence data for this patent did not appear in the printed specification
 CC but was obtained in electronic format directly from USPTO at
 CC seqdat.uspto.gov/sequence.html.

XX

SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 12; Length 915;
 Best Local Similarity 50.5% Pred. No. 2. 4e-13;
 Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;

Qy	31	CCATTCTGACCAATGACCAAGTGAAGAGATTGATAGCCAAGAGCCAAGCTGCCGATACG	90
Db	328	OCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGCCACTGGCTGTTGAAGCTGGTGTATC	387
Qy	91	GATGCAOGTGAGCTTCCTCGTGAATAGCAATATCAGACTGGCTGGTCCGTOGTCCAGCGC	150
Db	388	GAAGCCAAACAAACGTCTTGGGAAGCCAATCTTGTGGTTGTTCCATTGCCAACCGC	447
Qy	151	TTTATCAACCGCGGTATGAACGGGATGATTGTTCAGATCGGTCGATTGGCTGCTC	210
Db	448	TATGTCGGTGTGGTAGCAGTCCCTGACTTGATTCAAGAAGGAAATATGGCCTTGATG	507
Qy	211	AAGGCGTTGACAAGTTGACTATTCAAAGGGTCAAGTTCAACTTATGCAACTTGG	270
Db	508	AAGGCGTTGACAAGTTGACTATTCAAAGGGTCAAGTTCAACTTATGCAACTTGG	567
Qy	271	ATGATCATCGGAGAAATTCAACGCTTTTGCAGATGACG - - GTACGGTTAAGTCAGT	327
Db	568	TGGATTCGTAGGCTATCACTCGTGCATTGCAGACCAAGCTCGTACCATCGTATCCCA	627
Qy	328	CGATCGTAAAAGAAACAGCGATAAGGTGCGGGGATCAAAGGATGAATTGTACAAGCAA	387
Db	628	GTTCACATGGTGAAGACTATCAATAAAATTGGTTCGTGAACAGCGGAATCTCCTTCAAGAA	687
Qy	388	TTGGCGGTGCCCGAACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCAOGCGGGAGGAA	447
Db	688	TTGGGGCAAGATCGACACAGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG	747
Qy	448	GT 449	
Db	748	GT 749	

RESULT 10

AEJ68509

ID AEJ68509 standard; DNA; 915 BP.

XX

AC AEJ68509;

XX

DT 05-OCT-2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ: 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein product ion;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

KW antibiotic; neuroprotective; antiinflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

OS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS 1..915

FT /*tag= a

FT /product= "Streptococcus pneumoniae protein SEQ ID NO: 3757"

XX

PN US7074914-B1.

XX

PD 11-JUL-2006.

XX

PF 30-DEC-2004; 2004US-00028099.

XX

PR 02-JUL-1997; 97US-0051553P.

PR 12-MAY-1998; 98US-0085131P.

PR 30-JUN-1998; 98US-00107433.

PR 26-MAY-2000; 2000US-00583110.

PR 14-AUG-2003; 2003US-00640833.

XX

PA (SNFI) SANOFI PASTEUR LTEE.

XX

PI Doucette-Stamm L, Bush D, Zeng Q, Opperman T, Housewright CE;

XX

DR WPI; 2006-500481/51.

DR P-PSDB; AEJ71170.

XX

PT New isolated nucleic acid and polypeptide from Streptococcus pneumoniae, useful for diagnosing, preventing, or treating pathological conditions resulting from bacterial infections, e.g. S. pneumoniae infection.

PS Example; SEQ ID NO 1096; 29pp; English.

XX

CC The invention relates to an isolated nucleic acid, especially (AEJ68056), which encodes the Streptococcus pneumoniae protein of AEJ70717. This nucleic acid is one of 2661 disclosed protein-encoding nucleic acids (AEJ67414-AEJ70074) isolated from a Streptococcus pneumoniae strain 14453 genomic library whose predicted products (AEJ70075-AEJ72735) exhibit homology to known prokaryotic, eukaryotic or archaean open reading frames (ORFs) or proteins. The invention also relates to a recombinant expression vector comprising the nucleic acid of the invention operably linked to a transcription regulatory element; and a host cell comprising the recombinant expression vector. The Streptococcus pneumoniae nucleic acids and proteins of the invention are useful for diagnosing, preventing, or treating pathological conditions resulting from bacterial infections, especially infections caused by Streptococcus pneumoniae such as meningitis, bacteremia, pneumonia and otitis media. They may also be used in vaccine compositions for the treatment of Streptococcus pneumoniae infections and as targets for antibacterial drugs.

CC Additionally the nucleic acids are useful in the production of commercially important proteins such as enzymes for use in fermentation reactions or in the production of commercially useful metabolites. The present sequence represents a Streptococcus pneumoniae strain 14453 protein-encoding nucleic acid which was identified in the exemplification of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from the US patent office at seqdata.uspto.gov/sequence.html?DocID=7074914B1.

SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 21; Length 915;

Best Local Similarity 50.5% Pred. No. 2.4e-13;

Matches 213; Conservative 0; Missmatches 206; Indels 3; Gaps 1;

Qy 31 CCATTCTGACCAATGCCAAGTGAAAGATTGATAGCCAAGAGCCAGCTGGGATACG 90

Db 328 CCTCTCTTGCACCAATGAAGAGGGAGAAAGAGTTGGCACTGGCTGTTGAAGCTGGTGTATAC 387

Qy	91	GATGCAACGTGAGCTTCTCGTGAATACCAATATCAGACTGGCTGGTCCGTCGTCCAGCGC	150
Db	388	GAAGCCAAACAAACGTCTTGGGAAGCCAATCTTGGTTGGTGCATTGCCAACCGC	447
Qy	151	TTTATCAACCGCGGGTATGAAGCGGATGATTGTTTCAAGATCGGTTGCATTGGCTTGCTC	210
Db	448	TATGTCGGTGGTATGCAGTCCCTGACTTGAATTCAAGAAGGAAATATGGGCTTGATG	507
Qy	211	AAGGCCGTTGACAAGTTCGATCTTGTACGATGTGAGATTTCGACCTATGCCGTGCCA	270
Db	508	AAGGCCGTTGACAAGTGTGACTATTCAAAGGGTCAAGTTCAACTTATGCAACTTGG	567
Qy	271	ATGATCATCGGAGAAAATTCAACGCTTTTGCAGGATGACG - - GTACGGTTAAGGTCACT	327
Db	568	TGGATTCGTCAGGCTATCACTCGTGCATTGCAGACCAAGCTCGTACCATCCGATCCCA	627
Qy	328	CGATCGTAAAAGAAAACAGCGAATAAGGTGCAGGATCAAAGGATGAATTGTACAAGCAA	387
Db	628	GTTCACATGGTTGAAACTATCAATAAAATTGGTTCGTGAACAGCGGAATCTCCTTCAAGAA	687
Qy	388	TTCCGGCOGTGCCCGAACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCAOGCGGGAGGAA	447
Db	688	TTCCGGCAAGATCGACACAGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG	747
Qy	448	GT 449	
Db	748	GT 749	

RESULT 11

AEJ75484

ID AEJ75484 standard; DNA; 915 BP.

XX

AC AEJ75484;

XX

DT 05- OCT- 2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ: 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

KW antibacterial; neuropeptide; antiinflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

OS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS 1..915

FT /*tag= a

FT /product= "Streptococcus pneumoniae protein SEQ ID NO: 3757"

XX

PN US7081530-B1.

XX

PD 25- JUL- 2006.

XX

PF 30- DEC- 2004; 2004US- 00028291.

XX

PR 02- JUL- 1997; 97US- 0051553P.

PR 12- MAY- 1998; 98US- 0085131P.

PR 30- JUN- 1998; 98US- 00107433.

PR 26- MAY- 2000; 2000US- 00583110.

PR 14- AUG 2003; 2003US- 00640833.

XX

PA (SNFI) SANOFI PASTEUR LTEE.

XX

PI Doucette-Stamm L, Bush D, Zeng Q, Opperman T, Housewright CE;

XX

DR WPI ; 2006-518920/ 53.
 DR P- PSDB; AEJ78145.
 XX
 PT New isolated Streptococcus pneumoniae nucleic acid, useful as a molecular target for detecting, diagnosing, preventing, or treating a pathological condition resulting from bacterial infection.
 XX
 PS Example; SEQ ID NO 1096; 29pp; English.
 XX
 CC The invention relates to an isolated nucleic acid, especially (AEJ75443), which encodes the Streptococcus pneumoniae protein of AEJ78104. This nucleic acid is one of 2661 disclosed protein-encoding nucleic acids (AEJ74389-AEJ77049) isolated from a Streptococcus pneumoniae strain 14453 genomic library whose predicted products (AEJ77050-AEJ79710) exhibit homology to known prokaryotic, eukaryotic or archaean open reading frames (ORFs) or proteins. The invention also relates to a recombinant expression vector comprising the nucleic acid of the invention operably linked to a transcription regulatory element; and a host cell comprising the recombinant expression vector. The Streptococcus pneumoniae nucleic acids and proteins of the invention are useful for diagnosing, preventing, or treating pathological conditions resulting from bacterial infections, especially infections caused by Streptococcus pneumoniae such as meningitis, bacteremia, pneumonia and otitis media. They may also be used in vaccine compositions for the treatment of Streptococcus pneumoniae infections and as targets for antibacterial drugs.
 CC Additionally the nucleic acids are useful in the production of commercially important proteins such as enzymes for use in fermentation reactions or in the production of commercially useful metabolites. The present sequence represents a Streptococcus pneumoniae strain 14453 protein-encoding nucleic acid which was identified in the exemplification of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from the US patent office at seqdat.uspto.gov/sequence.html ?DocID=7081530B1.
 XX
 SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;
 Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2.4e-13;
 Matches 213; Conservative 0; Missmatches 206; Indels 3; Gaps 1;

Qy	31	CCATTCTGACCAATGACCAAGTGAAGAGATTGATGCCAAGAGCCAAGCTGGCGATACG	90
Db	328	CCTCTCTGACCAATGAAGAGGAGAAAGAGTTGCCACTGGCTGTTGAAGCTGGTGTATC	387
Qy	91	GATGCACGTGAGCTTCCTCGTGAATACCAATATCAGACTGGCTGGTCCGTCGTCAGCGC	150
Db	388	GAAGCCAAACAAACGCTTGGGAAGCCAATCTCGTTGGTTGTTCCATTGCCAACGC	447
Qy	151	TTTATCAAACCGGGGATGAAGGGATGATTGTTCAGATGGTGCAATTGGCTTGCTC	210
Db	448	TATGTCGGTGGTATGCAGTTCTTGACTTCAAGAAGGAAATATGGCTTGATG	507
Qy	211	AAGGCCGTTGACAAGTTCGATCTTCGTACGATGTGAGATTTCGACCTATGGGTGCCA	270
Db	508	AAGGCCGTTGACAAGTTGACTATTCTAAAGGGTCAAGTTCAACTATGCAACTTGG	567
Qy	271	ATGATCATGGAGAAATTCAACGCTTTGGCGATGACG--GTACGGTTAAGGTCACT	327
Db	568	TGGATTCGTCAAGCTATCACTCGTCTTGCAGACCAAGCTCGTACCATCCGTATCCC	627
Qy	328	CGATCGTTAAAGAAACAGCGAATAAGGTGCCGGATCAAAGGATGAATTGTACAAGCAA	387
Db	628	GTTCACATGGTCAAACATCAATAATTGGTCTGTGAACAGCGGAATCTCCTCAAGAA	687
Qy	388	TTCGGCCGTGCCCGCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCACGCCGGAGGAA	447
Db	688	TTGGGCCAAGATCGACACACAGATTGCTGAACGAATGGATATGACACCTGATAAG	747

Qy 448 GT 449
 Db 748 GT 749

RESULT 12

AEJ82844

ID AEJ82844 standard; DNA; 915 BP.

XX

AC AEJ82844;

XX

DT 19-OCT-2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

KW antibacterial; neuroprotective; antiinflammatory; respiratory-gen.

KW auditory; gene; ds.

XX

OS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS 1..915

FT /*tag= a

FT /product= "Streptococcus pneumoniae protein SEQ ID

FT NO: 3757"

XX

PN US7098023-B1.

XX

PD 29-AUG-2006.

XX

PF 30-DEC-2004; 2004US-00027878.

XX

PR 02-JUL-1997; 97US-0051553P.

PR 12-MAY-1998; 98US-0085131P.

PR 30-JUN-1998; 98US-00107433.

PR 26-MAY-2000; 2000US-00583110.

PR 14-AUG-2003; 2003US-00640833.

XX

PA (SNFI) SANOFI PASTEUR LTD.

XX

PI Doucette-Stamm L, Bush D, Zeng Q, Opperman T, Housewright CE;

XX

DR WPI; 2006-584390/60.

DR P-PSDB; AEJ85505.

XX

PT New isolated Streptococcus pneumoniae nucleic acid and polypeptide, useful as vaccines and as targets for diagnosing, preventing, or treating pathological conditions resulting from S. pneumoniae bacterial infection.

XX

PS Example; SEQ ID NO 1096; 29pp; English.

XX

CC The invention relates to an isolated nucleic acid, especially (AEJ84330), which encodes the Streptococcus pneumoniae protein of AEJ86991. This nucleic acid is one of 2661 disclosed protein-encoding nucleic acids (AEJ81749-AEJ84409) isolated from a Streptococcus pneumoniae strain 14453 genomic library whose predicted products (AEJ84410-AEJ87070) exhibit homology to known prokaryotic, eukaryotic or archaeal open reading frames (ORFs) or proteins. The invention also relates to a recombinant expression vector comprising the nucleic acid of the invention operably linked to a transcription regulatory element; and a host cell comprising the recombinant expression vector. The Streptococcus pneumoniae nucleic acids and proteins of the invention are useful for diagnosing, preventing, or treating pathological conditions resulting from bacterial infections, especially infections caused by Streptococcus pneumoniae such as meningitis, bacteremia, pneumonia and otitis media. They may also be used in vaccine compositions for the treatment of Streptococcus

CC pneumoni ae i nf ect i on s and as t arget s for anti bact eri al dr ugs.
 CC Additi onal ly the nucl ei c aci ds are useful i n the production of
 CC commer ci al ly i mportant prot ei ns such as enzymes for use i n fermentati on
 CC reacti ons or i n the producti on of commer ci al ly useful metaboli tes. The
 CC present sequence represents a St reptococcus pneumoni ae strai n 14453
 CC prot ei n-encoding nucl ei c aci d whi ch was i dentified i n the exemplifi cati on
 CC of the i nvention. Note: The sequence data for this patent did not form
 CC part of the printed specifi cati on, but was obt ai ned i n electronic format
 CC di rectly from the US patent office at seqdat a.uspto.gov/sequence.html ?DocID=7098023B1.
 XX

SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2.4e-13;
 Matches 213; Conservative 0; Missmatches 206; Indels 3; Gaps 1;

Qy	31	CCATTCTGACCAATGACCAAGTGAAGAGATTGATGCCAAGGCCAAGCTGGCGATACG	90
Db	328	CCTCTCTGACCAATGAAGAGGAGAAAGAGTGGCACTGGCTGTTGAAGCTGGTGTATC	387
Qy	91	GATGCACGTGAGCTTCGTGAATAGCAATATCAGACTGGCTGGTCCGTGTCAGCGC	150
Db	388	GAAGCCAAACAAACGCTTGCGGAACCCAATCTCGTTGGTTGTTCCATTGCCAACGC	447
Qy	151	TTTATCAACCGGGATGAAGCGGATGATTGTTAGATCGCTGGCTGGCTGGCTGCTC	210
Db	448	TATGTCGGTGGTATGCAGTCCTGACTTGAATTCAAGAAGGAATATGGCTTGATG	507
Qy	211	AAGGCCGTTGACAAGTTGACTATTCAAAGGGTTCAAGTTCAACTTATGCCACTTGG	270
Db	508	AAGGCCGTTGACAAGTTGACTATTCAAAGGGTTCAAGTTCAACTTATGCCACTTGG	567
Qy	271	ATGATCATCGGAGAAATTCAACGCTTTTGGCGATGACG-----GTACGGTTAAGGTCA	327
Db	568	TGGATTCGTCAGGCTATCACTCGTGCATTGCAGACCAAGCTCGTACCATCCGTATCCC	627
Qy	328	CGATCGTAAAAGAAACAGCGAATAAGGTGGCGATCAAAGGATGAATTGTACAAGCAA	387
Db	628	GTTCACATGGTGAAACTATCAATAATTGGTTCGTGAACAGCGGAATCTCCTTCAAGAA	687
Qy	388	TTCGGCCGTGCCCGCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCAOGCCGGAGGAA	447
Db	688	TTGGGCCAGATCGACACCAGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG	747
Qy	448	GT 449	
Db	748	GT 749	

RESULT 13

AEL05163

ID AEL05163 standard; DNA; 915 BP.

XX

AC AEL05163;

XX

DT 30-NOV-2006 (first entry)

XX

DE St reptococcus pneumoni ae strai n 14453 prot ei n-encoding DNA, SEQ: 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein producti on;
 KW bact eri al i nf ecti on; St reptococcus pneumoni ae i nf ecti on;
 KW bact eri al meni ngiti s; bact eri al pneumoni a; bact er emia; otiti s medi a;
 KW ant i bact eri al ; neuroprot ecti ve; ant i infl ammat ory; respi rat ory- gen.;
 KW audito ry; gene; ds.

XX

OS St reptococcus pneumoni ae; strai n 14453.

XX

FH Key Location/Qualifiers

FT CDS 1..915
 FT /*tag= a
 FT /product= "Streptococcus pneumoniae protein SEQ ID
 NO:3757"
 XX
 PN US7115731-B1.
 XX
 PD 03- OCT- 2006.
 XX
 PF 30- DEC- 2004; 2004US- 00027399.
 XX
 PR 02- JUL- 1997; 97US- 0051553P.
 PR 12- MAY- 1998; 98US- 0085131P.
 PR 30- JUN- 1998; 98US- 00107433.
 PR 26- MAY- 2000; 2000US- 00583110.
 PR 14- AUG 2003; 2003US- 00640833.
 XX
 PA (SNFI) SANOFI PASTEUR LTD.
 XX
 PI Doucette- Stamm L, Bush D, Zeng Q, Opperman T, Housewright CE;
 XX
 DR WPI ; 2006- 744050/ 76.
 DR P- PSDB; AEL07824.
 XX
 PT New nucleic acid encoding Streptococcus pneumoniae polypeptide, useful
 PT for detecting, preventing, and treating pathological conditions resulting
 PT from bacterial infection.
 XX
 PS Example; SEQ ID NO 1096; 29pp; English.
 XX
 CC The invention relates to an isolated nucleic acid, especially (AEL05123),
 CC which encodes the Streptococcus pneumoniae protein of AEL07784. This
 CC nucleic acid is one of 2661 disclosed protein-encoding nucleic acids
 CC (AEL04068-AEL06728) isolated from a Streptococcus pneumoniae strain 14453
 CC genomic library whose predicted products (AEL06729-AEL09389) exhibit
 CC homology to known prokaryotic, eukaryotic or archaeal open reading frames
 CC (ORFs) or proteins. The invention also relates to a recombinant
 CC expression vector comprising the nucleic acid of the invention operably
 CC linked to a transcription regulatory element; and a host cell comprising
 CC the recombinant expression vector. The Streptococcus pneumoniae nucleic
 CC acids and proteins of the invention are useful for diagnosing,
 CC preventing, or treating pathological conditions resulting from bacterial
 CC infections, especially infections caused by Streptococcus pneumoniae such
 CC as meningitis, bacteremia, pneumonia and otitis media. They may also be
 CC used in vaccine compositions for the treatment of Streptococcus
 CC pneumoniae infections and as targets for antibacterial drugs.
 CC Additionally the nucleic acids are useful in the production of
 CC commercially important proteins such as enzymes for use in fermentation
 CC reactions or in the production of commercially useful metabolites. The
 CC present sequence represents a Streptococcus pneumoniae strain 14453
 CC protein-encoding nucleic acid which was identified in the exemplification
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from the US patent office at
 CC seqdata.uspto.gov/sequence.html?DocID=7115731B1.
 XX
 SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;
 Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2.4e-13;
 Matches 213; Conservative 0; Missmatches 206; Indels 3; Gaps 1;
 Qy 31 CCATTCTGACCAATGCCAGTGAAAGATTGATAGCCAAGAGCCAGCTGGCGATACG 90
 Db 328 CCTCTCTTGCACCATGAAGAGGGAGAAAGAGTTGGCACTGGCTGTTGAAGCTGGTATAC 387
 Qy 91 GATGCACGTGAGCTTCCTCGTGAATAGCAATATCAGACTGGCTGGTCCGTGTCAGCGC 150
 Db 388 GAAGCCAAACAACGTCTGGGAAGCCAACTTCTGTTGGTTCATTGCCAACGC 447

Qy 151 TTTATCAAACGGGGTATGAAGCGGATGATTGTTCAGATGGTGCATTGGCTGCTC 210
 Db 448 TATGTCGGTCGTGGTATGCAGTCCCTGACTTCAAGAAGGAAATATGGCTTGATG 507
 Qy 211 AAGGCCGTTGACAAGTTGATCTTCGTACGATGTGAGATTTGACCTATGGGTGCCA 270
 Db 508 AAGGCCGTTGACAAGTTGACTATTCTAAAGGGTTCAAGTTCAACTTATGCAACTTGG 567
 Qy 271 ATGATCATCGGAGAAATTCAACGCTTTTGGCGATGACG--GTACGGTTAACGGTCACT 327
 Db 568 TGGATTTCGTCAAGCTATCACTCGTCTATTGCAGACCAAGCTCGTAACCACCGTATCCCA 627
 Qy 328 CGATCGTTAAAGAAAACAGCGAATAAGGTGGGGGATCAAAGGATGAATTGTACAAGCAA 387
 Db 628 GTTCACATGGTTGAAACTATCAATAAAATTGGTTCGTGAACACCGGAATCTCCTTCAAGAA 687
 Qy 388 TTGGGCCGTGCCCGCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCAOGCOGGAGGAA 447
 Db 688 TTGGGCCAAGATCGACACCCAGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG 747
 Qy 448 GT 449
 Db 748 GT 749

RESULT 14

AEL12413

ID AEL12413 standard; DNA; 915 BP.

XX

AC AEL12413;

XX

DT 28- DEC- 2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ: 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteraemia; otitis media;

KW antibacterial; neuroneurotrophic; antiinflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

OS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS 1..915

FT /tag= a

FT /product= "Streptococcus pneumoniae protein SEQ ID

FT NO: 3757"

XX

PN US7122368-B1.

XX

PD 17- OCT- 2006.

XX

PF 30- DEC- 2004; 2004US- 00027877.

XX

PR 02- JUL- 1997; 97US- 0051553P.

PR 12- MAY- 1998; 98US- 0085131P.

PR 30- JUN- 1998; 98US- 00107433.

PR 26- MAY- 2000; 2000US- 00583110.

PR 14- AUG- 2003; 2003US- 00640833.

XX

PA (SNFI) SANOFI PASTEUR LTD.

XX

PI Doucette- Stamm L, Bush D, Zeng Q, Opperman T, Housewright CE;

XX

DR WPI ; 2006- 812612/ 82.

DR P- PSDB; AEL15074.

XX

PT New isolated nucleic acid and polypeptide isolated from strain 14453 of Streptococcus pneumoniae, useful for diagnosing, preventing, or treating bacterial infections, e.g. S. pneumoniae infection.

XX

PS Example; SEQ ID NO 1096; 29pp; English.

XX

CC The invention relates to an isolated nucleic acid, especially (AEL12919),
 CC which encodes the Streptococcus pneumoniae protein of AEL15580. This
 CC nucleic acid is one of 2661 disclosed protein-encoding nucleic acids
 CC (AEL11318-AEL13978) isolated from a Streptococcus pneumoniae strain 14453
 CC genomic library whose predicted products (AEL13979-AEL16639) exhibit
 CC homology to known prokaryotic, eukaryotic or archaeal open reading frames
 CC (ORFs) or proteins. The invention also relates to a recombinant
 CC expression vector comprising the nucleic acid of the invention operably
 CC linked to a transcription regulatory element; and a host cell comprising
 CC the recombinant expression vector. The Streptococcus pneumoniae nucleic
 CC acids and proteins of the invention are useful for diagnosing,
 CC preventing, or treating pathological conditions resulting from bacterial
 CC infections, especially infections caused by Streptococcus pneumoniae such
 CC as meningitis, bacteremia, pneumonia and otitis media. They may also be
 CC used in vaccine compositions for the treatment of Streptococcus
 CC pneumoniae infections and as targets for antibacterial drugs.
 CC Additionally the nucleic acids are useful in the production of
 CC commercially important proteins such as enzymes for use in fermentation
 CC reactions or in the production of commercially useful metabolites. The
 CC present sequence represents a Streptococcus pneumoniae strain 14453
 CC protein-encoding nucleic acid which was identified in the exemplification
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from the US patent office at
 CC seqdata.uspto.gov/sequence.html?DocID=7122368B1.

XX

SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2. 4e-13;
 Matches 213; Conservative 0; Missmatches 206; Indels 3; Gaps 1;

Qy	31	CCATTCTGACCAATGCCAAGTGAAGATTGATAGCCAAGAGCCAAGCTGGGATACG	90
Db	328	CCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTTGAAGCTGGTATATC	387
Qy	91	GATGCACGTGAGCTCTCGTGAATAGCAATATCAGACTGGCTGGTCCGTGTCAGCGC	150
Db	388	GAAGCCAAACAACGCTTGGGAACCCAATCTTGGTTGGTTGCATTGCAAAACGC	447
Qy	151	TTTATCAACCGGGATGAAGCGGATGATTGTTCAAGATCGGTCATTGGCTTGCTC	210
Db	448	TATGTCGGTGTGGTATGCAGTTCTTGACTTGAATCAAGAAGGAAATATGGCTTGATG	507
Qy	211	AAGGCGTTGACAAGTTGACTCTTCAAGGTTCAAGTTCAACTTATGCAACTTGG	270
Db	508	AAGGCGGTTGACAAGTTGACTATTCAAAGGTTCAAGTTCAACTTATGCAACTTGG	567
Qy	271	ATGATCATCGGAGAAATTCAACGCTTTTGCCTGGATGACGTTAACGGTTAAGGTCA	327
Db	568	TGGATTCGTCAGGCTATCACTCGTCTATTGCAGACCAAGCTCGTACCATCGTATCCC	627
Qy	328	CGATCGTAAAAGAAACAGCGATAAGGTGGGGGATCAAAGGATGAATTGTACAAGCAA	387
Db	628	GTTCACATGGTGAAGACTATCAATAATTGGTTCGTGAACAGCGGAATCTCCTTCAAGAA	687
Qy	388	TTCGGCGTGCCCCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCAACGCGGAGGAA	447
Db	688	TTGGGCAAGATCGACACCGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG	747
Qy	448	GT 449	
Db	748	GT 749	

RESULT 15

AEL50821

ID AEL50821 standard; DNA; 915 BP.

XX

AC AEL50821;

XX

DT 28- DEC- 2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ: 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteraemia; otitis media;

KW antibacterial; neuropeptide; antiinflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

OS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS 1..915

FT /*tag= a

FT /product = "Streptococcus pneumoniae protein SEQ ID NO: 3757"

XX

PN US7129340-B1.

XX

PD 31- OCT- 2006.

XX

PF 30- DEC- 2004; 2004US- 00028457.

XX

PR 02- JUL- 1997; 97US- 0051553P.

PR 12- MAY- 1998; 98US- 0085131P.

PR 30- JUN- 1998; 98US- 00107433.

PR 26- MAY- 2000; 2000US- 00583110.

PR 14- AUG- 2003; 2003US- 00640833.

XX

PA (SNFI) SANOFI PASTEUR LTD.

XX

PI Doucette-Stamm L, Bush D, Zeng Q, Opperman T, Housewright CE;

XX

DR WPI; 2006- 812716/82.

DR P-PSDB; AEL53482.

XX

PT New isolated nucleic acid and polypeptide isolated from Streptococcus

PT pneumoniae, useful as components of antibacterial vaccines, and for

PT diagnosing or treating S. pneumoniae and other Streptococcus infections.

XX

PS Example; SEQ ID NO 1096; 29pp; English.

XX

CC The invention relates to an isolated nucleic acid, especially (AEL52290),
 CC which encodes the Streptococcus pneumoniae protein of AEL54951. This
 CC nucleic acid is one of 2661 disclosed protein-encoding nucleic acids
 CC (AEL49726-AEL52386) isolated from a Streptococcus pneumoniae strain 14453
 CC genomic library whose predicted products (AEL52387-AEL55047) exhibit
 CC homology to known prokaryotic, eukaryotic or archaeal open reading frames
 CC (ORFs) or proteins. The invention also relates to a recombinant
 CC expression vector comprising the nucleic acid of the invention operably
 CC linked to a transcription regulatory element; and a host cell comprising
 CC the recombinant expression vector. The Streptococcus pneumoniae nucleic
 CC acids and proteins of the invention are useful for diagnosing,
 CC preventing, or treating pathological conditions resulting from bacterial
 CC infections, especially infections caused by Streptococcus pneumoniae such
 CC as meningitis, bacteraemia, pneumonia and otitis media. They may also be
 CC used in vaccine compositions for the treatment of Streptococcus
 CC pneumoniae infections and as targets for antibacterial drugs.
 CC Additionally the nucleic acids are useful in the production of
 CC commercially important proteins such as enzymes for use in fermentation

CC reactions or in the production of commercially useful metabolites. The CC present sequence represents a Streptococcus pneumoniae strain 14453 CC protein-encoding nucleic acid which was identified in the exemplification CC of the invention. Note: The sequence data for this patent did not form CC part of the printed specification, but was obtained in electronic format CC directly from the US patent office at CC seqdat.uspto.gov/sequence.html?DocID=7129340B1.

XX

SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2.4e-13;
 Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;

Qy	31	CCATTCTGACCAATGACCAAGTGAAAGATTGATAGCCAAGAGGCCAGCTGGGATACG	90
Db	328	CCTCTCTGACCAATGAAGAGGAGAAAAGAGTGGCACTGGCTGTTGAAGCTGGT	GATATC 387
Qy	91	GATGCACGTGAGCTTCGTGAATAGCAATATCAGACTGGCTGGTCCGTCGTCAGCGC	150
Db	388	GAAGCCAAACAAACGCTTGGGAACCCAATCTCGTTGGTTGTTCCATTGCCAACGC	447
Qy	151	TTTATCAAACGGGGATGAAGGGATGATTGTTAGATGGTGCATTGGCTGCTC	210
Db	448	TATGTCGGTCGTGGTATGCAGTTCTTGACTTGAATTCAAGAAGGAATATGGCTTGATG	507
Qy	211	AAGGCCGTTGACAAGTTGACTATTCTAAAGGGTTCAAGTTCAACTTATGCCACTTGG	270
Db	508	AAGGCCGTTGACAAGTTGACTATTCTAAAGGGTTCAAGTTCAACTTATGCCACTTGG	567
Qy	271	ATGATCATCGGAGAAATTCAACGCTTTTGGGGATGACG--GTACGGTTAAGGTCA	327
Db	568	TGGATTCGTCAGGCTATCACTCGTCTATTGCAGACCAAGCTCGTACCATCCGTATCCC	627
Qy	328	CGATCGTTAAAGAAAACAGCGAATAAGGTGGGGGATCAAAGGATGAATTGTACAAGCAA	387
Db	628	GTTCACATGGTGAAACTATCAATAAATTGGTCGTGAACAGCGGAATCTCCTTCAAGAA	687
Qy	388	TTCGGCCGTGCCCGCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCAOGCCGGAGGAA	447
Db	688	TTGGGGCAAGATCGACACCAGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG	747
Qy	448	GT 449	
Db	748	GT 749	

Search completed: November 4, 2008, 17:14:39
 Job time : 247 secs

SCORE 3.0